A PHASE 1/1B DOSE‐ESCALATION TRIAL EVALUATING CPI‐818, AN ORAL INTERLEUKIN‐2‐INDUCIBLE T‐CELL KINASE INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY T‐CELL LYMPHOMA. (12th June 2019) - Mobasher, M.; Miller, R.; Janc, J.; Kwei, L.; Barker, C.; Mohammady, A.; Luciano, G.; Radeski, D.; Kim, Y.; Khodadoust, M.; Horwitz, S.